This metabolic reprogramming led to increased α2,6-sialylation of PD-L1, which in turn elevated its protein stability and binding affinity to PD-1, ultimately resulting in T cell dysfunction and promoting tumor immune evasion. The gene discussed is CD274; the disease is neoplasm.